サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1455696

非結核性抗酸菌（NTM）市場：薬剤クラス別、流通チャネル別、国別、地域別 - 産業分析、市場規模、市場シェア、予測、2024年～2032年

Nontuberculous Mycobacteria Market, By Drug Class, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 260 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
非結核性抗酸菌（NTM）市場：薬剤クラス別、流通チャネル別、国別、地域別 - 産業分析、市場規模、市場シェア、予測、2024年～2032年
出版日: 2024年03月04日
発行: AnalystView Market Insights
ページ情報: 英文 260 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

レポートハイライト

非結核性抗酸菌（NTM）市場規模は2023年に93億2,034万米ドルとなり、2024年から2032年にかけてCAGR 3.14%で拡大

非結核性抗酸菌（NTM）市場- 市場力学

非結核性抗酸菌（NTM）肺疾患の発生は、特に世界の高齢者人口の間で増加しており、市場の成長を促進すると予測されます。

世界人口の高齢化に伴い、高齢者の数が大幅に増加しています。加齢はNTM肺疾患の危険因子であるため、高齢者人口の増加は疾患の発生率の増加に寄与し、それによって診断および治療ソリューションに対するより高い需要を生み出すと予測されます。NTM肺疾患に関する医療プロバイダーや患者の意識が向上し、医療サービスへのアクセスが改善された結果、診断と治療の割合が増加しています。National Health Serviceによると、2021年、呼吸器疾患による死亡率（主原因または関連原因）は高齢者に多く見られました（呼吸器疾患による死亡の73%は75歳以上で、全死亡の67%は75歳以上）。さらに、ハイスループットシークエンシングや培養法の強化といった診断技術の進歩は、市場に成長機会をもたらす可能性があります。とはいえ、治療費の高さが市場の成長を阻害する可能性もあります。

非結核性抗酸菌（NTM）市場-主要インサイト

弊社リサーチアナリストの分析によると、世界市場は予測期間（2024-2032年）に約3.14%のCAGRで毎年成長すると推定されます。

薬剤クラス別では、経口抗生物質が2023年に最大の市場シェアを示すと予測されます。

地域別では、北米が2023年の売上高を牽引

非結核性抗酸菌（NTM）市場-セグメンテーション分析：

非結核性抗酸菌（NTM）の世界市場は薬剤クラス別、流通チャネル別、地域別に区分されます。

市場は薬剤クラス別に4つに区分される：経口抗生物質、静脈内抗生物質、吐き気止め、抗生物質のネブライザーです。経口抗生物質カテゴリーが市場で最大のシェアを占めています。非結核性抗酸菌（NTM）感染症の治療に使用される経口抗生物質の市場には、NTM関連疾患の流行、既存の抗生物質の有効性、治療プロトコル、規制当局の認可など、さまざまな要因が影響しています。

市場は流通チャネルによって3つのセグメントに分類される：病院薬局、小売薬局、オンライン薬局です。非結核性抗酸菌（NTM）感染症用の抗生物質やその他の医薬品を製造する製薬会社は、従来の医薬品流通チャネルを通じて製品を販売しています。

非結核性抗酸菌（NTM）市場-地理的洞察

非結核性抗酸菌（NTM）市場は、北米、ラテンアメリカ、欧州、アジア太平洋、中東・アフリカといった様々な地域にまたがっています。これらの地域は、事業活動を行っている国に基づいてさらに区分されます。市場の成長は北米が支配的であると予想されるが、その主な理由は、新薬開発のための研究努力の増加と医療費の上昇です。NTM感染症に対する新たな抗生物質や治療レジメンの発見に焦点を当てた研究開発努力が顕著に急増しています。米国では、医療費は2021年に2.7％増加し、4兆3,000億米ドル、一人当たり1万2,914米ドルに達します。この伸び率は、米国医師会が発表した2020年の伸び率（10.3％）を大幅に下回っています。欧州は、主に感染症率の上昇により、この市場で2番目に大きな地域となっています。

非結核性抗酸菌（NTM）市場-競合情勢：

非結核性抗酸菌（NTM）感染症に対する抗生物質やその他の治療薬の開発を専門とするさまざまな製薬企業が、この市場における主な競合相手です。各社は、製品の有効性、安全性、価格設定などの要素や、市場参入を確保するための戦略に基づいて競争しています。競合には、NTM菌に対してより優れた活性を持つ新しい抗生物質や、患者のアドヒアランスと転帰を改善する製剤を開発することも含まれます。NTM市場の競争は臨床開発パイプラインにも及び、各社は新たな治療法の導入や既存製品の適応拡大を目指しています。全体として、NTM市場における競合は、製品の差別化、臨床開発への取り組み、規制要因、市場参入計画、研究開発、共同研究によって形成されています。

目次

第1章 非結核性抗酸菌（NTM）市場概要

  • 調査範囲
  • 市場推定年数

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 非結核性抗酸菌（NTM）の主要な市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 今後の市場動向

第4章 非結核性抗酸菌（NTM）産業の調査

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しのマッピング
  • 規制枠組みの分析

第5章 非結核性抗酸菌（NTM）市場：COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19後の影響分析

第6章 非結核性抗酸菌（NTM）の市場情勢

  • 非結核性抗酸菌（NTM）市場シェア分析、2023年
  • 主要メーカー別の内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 非結核性抗酸菌（NTM）市場-薬剤クラス別

  • 概要
    • 薬剤クラス別のセグメントシェア分析
    • 経口抗生物質
    • IV抗生物質
    • 吐き気止め
    • 抗生物質のネブライザー

第8章 非結核性抗酸菌（NTM）市場- 流通チャネル別

  • 概要
    • 販売チャネル別のセグメントシェア分析
    • 病院薬局
    • 小売薬局
    • オンライン薬局

第9章 非結核性抗酸菌（NTM）市場- 地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東とアフリカ
    • 概要
    • 中東とアフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第10章 主要ベンダー分析- 非結核性抗酸菌（NTM）産業

  • 競合ダッシュボード
  • 企業プロファイル
    • Insmed, RedHill Biopharma Ltd
    • Novartis AG
    • Paratek Pharmaceuticals Inc
    • Janssen
    • RevImmune
    • Nobelpharma Co Ltd
    • Others

第11章 アナリストの全方位展望

図表

List of Tables

  • TABLE List of data Drug Classs
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Nontuberculous Mycobacteria Market: Drug Class Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Drug Class
  • TABLE Global Nontuberculous Mycobacteria Market, by Drug Class 2019-2032 (USD Million)
  • TABLE Nontuberculous Mycobacteria Market: Distribution Channel Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution Channel
  • TABLE Global Nontuberculous Mycobacteria Market, by Distribution Channel 2019-2032 (USD Million)
  • TABLE Nontuberculous Mycobacteria Market: Regional snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Nontuberculous Mycobacteria Market, by Region 2019-2032 (USD Million)
  • TABLE North America Nontuberculous Mycobacteria Market, by Country, 2019-2032 (USD Million)
  • TABLE North America Nontuberculous Mycobacteria Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE North America Nontuberculous Mycobacteria Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Europe Nontuberculous Mycobacteria Market, by Country, 2019-2032 (USD Million)
  • TABLE Europe Nontuberculous Mycobacteria Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Europe Nontuberculous Mycobacteria Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Asia Pacific Nontuberculous Mycobacteria Market, by Country, 2019-2032 (USD Million)
  • TABLE Asia Pacific Nontuberculous Mycobacteria Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Asia Pacific Nontuberculous Mycobacteria Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Latin America Nontuberculous Mycobacteria Market, by Country, 2019-2032 (USD Million)
  • TABLE Latin America Nontuberculous Mycobacteria Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Latin America Nontuberculous Mycobacteria Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Nontuberculous Mycobacteria Market, by Country, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Nontuberculous Mycobacteria Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Nontuberculous Mycobacteria Market, by Distribution Channel, 2019-2032 (USD Million)
目次
Product Code: ANV2359

REPORT HIGHLIGHT

Nontuberculous Mycobacteria Market size was valued at USD 9,320.34 Million in 2023, expanding at a CAGR of 3.14% from 2024 to 2032.

Nontuberculous mycobacteria are a collection of bacteria that naturally exist in soil, water, and dust all over the world. Non-tuberculous mycobacteria (NTM) refers to a group of over 190 species of Mycobacterium, excluding Mycobacterium tuberculosis and Mycobacterium leprae. These microorganisms are present everywhere in the environment, especially in soil and water sources, and are increasingly being recognized as a cause of human diseases. Non-tuberculous mycobacteria can infect not only individuals with weakened immune systems but also those who are otherwise healthy. The diagnosis and management of NTM infections pose numerous challenges.

Nontuberculous Mycobacteria Market- Market Dynamics

Increasing occurrence of nontuberculous mycobacterial lung illness, particularly amongst the older population worldwide, is projected to propel market's growth.

The aging global population is experiencing a significant rise in the number of elderly individuals. Due to the fact that age is a risk factor for NTM lung disease, the increasing elderly demographic is anticipated to contribute to the growing incidence of the illness, thereby creating a higher demand for diagnostic and therapeutic solutions. The improved awareness among healthcare providers and patients regarding NTM lung disease, along with better access to healthcare services, has resulted in increased rates of diagnosis and treatment. According to the National Health Service, in 2021, the mortality rate from respiratory conditions (as either the primary or associated cause) was more prevalent among older individuals (73% of respiratory deaths occurred in individuals aged 75 and above, compared to 67% for total deaths). Additionally, advancements in diagnostic techniques, such as high-throughput sequencing and enhanced culture methods, could present growth opportunities for the market. Nevertheless, the high cost of treatment may impede the market's growth.

Nontuberculous Mycobacteria Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 3.14% over the forecast period (2024-2032)

Based on Drug Class segmentation, Oral Antibiotics was predicted to show maximum market share in the year 2023

On the basis of region, North America was the leading revenue generator in 2023

Nontuberculous Mycobacteria Market- Segmentation Analysis:

The Global Nontuberculous Mycobacteria Market is segmented on the basis of Drug Class, Distribution Channel, and Region.

The market is segmented into four categories according to Drug Class: Oral Antibiotics, IV Antibiotics, Anti-Nausea, and Nebulized Antibiotics. The Oral Antibiotics category holds the largest share in the market. Various factors such as the prevalence of NTM-related diseases, the effectiveness of existing antibiotics, treatment protocols, and regulatory authorizations impact the market for oral antibiotics utilized in treating nontuberculous mycobacteria (NTM) infections.

The market is categorized into three segments according to the Distribution Channel: Hospital pharmacies, Retail pharmacies, and online pharmacies. Pharmaceutical companies that manufacture antibiotics and other medications for NTM infections distribute their products through conventional pharmaceutical distribution channels.

Nontuberculous Mycobacteria Market- Geographical Insights

This market is geographically spread across various regions, namely North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided based on the countries involved in business activities. The growth of the market is expected to be dominated by North America, primarily due to the increased research efforts in developing new medications and the rising healthcare expenses. There is a notable surge in research and development endeavors focused on discovering new antibiotics and treatment regimens for NTM infections. In the United States, health spending witnessed a 2.7% increase in 2021, reaching USD4.3 trillion or USD12, 914 per capita. This growth rate is significantly lower than that of 2020 (10.3%), stated by the American Medical Association. Europe holds the second-largest region for this market, primarily due to the rising rates of infectious illnesses.

Nontuberculous Mycobacteria Market- Competitive Landscape:

Various pharmaceutical companies specializing in the development of antibiotics and other therapeutics for NTM infections are the main competitors in this market. They compete based on factors like product effectiveness, safety, and pricing, as well as strategies to secure market access. Competition may also involve creating new antibiotics with better activity against NTM species or formulations that improve patient adherence and outcomes. The rivalry in the NTM market extends to the clinical development pipeline, where companies aim to introduce new treatments or expand existing product indications. Overall, competition in the NTM market is shaped by product differentiation, clinical development efforts, regulatory factors, market access plans, research and innovation, and collaborations.

Recent Developments:

On June 16, 2020, Novartis ILARIS (canakinumab) was approved by the US Food and Drug Administration (FDA) for a new indication to treat Adult-Onset Still's Disease (AOSD). The FDA granted approval for active Still's disease, which includes both systemic juvenile idiopathic arthritis (SJIA) and AOSD, in patients aged 2 years and older.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Insmed, RedHill Biopharma Ltd

Novartis AG

Paratek Pharmaceuticals Inc

Janssen

RevImmune

Nobelpharma Co Ltd

Others

GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Oral Antibiotics
  • IV Antibiotics
  • Anti Nausea
  • Nebulized Antibiotics

GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1.Nontuberculous Mycobacteria Market Overview

  • 1.1.Study Scope
  • 1.2.Market Estimation Years

2.Executive Summary

  • 2.1.Market Snippet
    • 2.1.1.Nontuberculous Mycobacteria Market Snippet by Drug Class
    • 2.1.2.Nontuberculous Mycobacteria Market Snippet by Distribution Channel
    • 2.1.3.Nontuberculous Mycobacteria Market Snippet by Country
    • 2.1.4.Nontuberculous Mycobacteria Market Snippet by Region
  • 2.2.Competitive Insights

3.Nontuberculous Mycobacteria Key Market Trends

  • 3.1.Nontuberculous Mycobacteria Market Drivers
    • 3.1.1.Impact Analysis of Market Drivers
  • 3.2.Nontuberculous Mycobacteria Market Restraints
    • 3.2.1.Impact Analysis of Market Restraints
  • 3.3.Nontuberculous Mycobacteria Market Opportunities
  • 3.4.Nontuberculous Mycobacteria Market Future Trends

4.Nontuberculous Mycobacteria Industry Study

  • 4.1.PEST Analysis
  • 4.2.Porter's Five Forces Analysis
  • 4.3.Growth Prospect Mapping
  • 4.4.Regulatory Framework Analysis

5.Nontuberculous Mycobacteria Market: COVID-19 Impact Analysis

  • 5.1.Pre-COVID-19 Impact Analysis
  • 5.2.Post-COVID-19 Impact Analysis
    • 5.2.1.Top Performing Segments
    • 5.2.2.Marginal Growth Segments
    • 5.2.3.Top Looser Segments
    • 5.2.4.Marginal Loss Segments

6.Nontuberculous Mycobacteria Market Landscape

  • 6.1.Nontuberculous Mycobacteria Market Share Analysis, 2023
  • 6.2.Breakdown Data, by Key Manufacturer
    • 6.2.1.Established Players' Analysis
    • 6.2.2.Emerging Players' Analysis

7.Nontuberculous Mycobacteria Market - By Drug Class

  • 7.1.Overview
    • 7.1.1.Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 7.1.2.Oral Antibiotics
    • 7.1.3.IV Antibiotics
    • 7.1.4.Anti-Nausea
    • 7.1.5.Nebulized Antibiotics

8.Nontuberculous Mycobacteria Market - By Distribution Channel

  • 8.1.Overview
    • 8.1.1.Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 8.1.2.Hospital pharmacies
    • 8.1.3.Retail pharmacies
    • 8.1.4.Online pharmacies

9.Nontuberculous Mycobacteria Market- By Geography

  • 9.1.Introduction
    • 9.1.1.Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 9.2.North America
    • 9.2.1.Overview
    • 9.2.2.Nontuberculous Mycobacteria Key Manufacturers in North America
    • 9.2.3.North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.2.4.North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.2.5.North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.2.6.U.S.
      • 9.2.6.1.Overview
      • 9.2.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.6.3.U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.2.6.4.U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.2.7.Canada
      • 9.2.7.1.Overview
      • 9.2.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.7.3.Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.2.7.4.Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.3.Europe
    • 9.3.1.Overview
    • 9.3.2.Nontuberculous Mycobacteria Key Manufacturers in Europe
    • 9.3.3.Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.3.4.Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.3.5.Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.6.Germany
      • 9.3.6.1.Overview
      • 9.3.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.6.3.Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.3.6.4.Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.7.Italy
      • 9.3.7.1.Overview
      • 9.3.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.7.3.Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.3.7.4.Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.8.United Kingdom
      • 9.3.8.1.Overview
      • 9.3.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.8.3.United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.3.8.4.United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.9.France
      • 9.3.9.1.Overview
      • 9.3.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.9.3.France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.3.9.4.France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.10.Russia
      • 9.3.10.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.10.2.Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.3.10.3.Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.11.Netherlands
      • 9.3.11.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.11.2.Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.3.11.3.Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.12.Sweden
      • 9.3.12.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.12.2.Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.3.12.3.Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.13.Poland
      • 9.3.13.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.13.2.Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.3.13.3.Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.14.Rest of Europe
      • 9.3.14.1.Overview
      • 9.3.14.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.14.3.Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.3.14.4.Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.4.Asia Pacific (APAC)
    • 9.4.1.Overview
    • 9.4.2.Nontuberculous Mycobacteria Key Manufacturers in Asia Pacific
    • 9.4.3.Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.4.4.Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.4.5.Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.6.India
      • 9.4.6.1.Overview
      • 9.4.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.6.3.India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.4.6.4.India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.7.China
      • 9.4.7.1.Overview
      • 9.4.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.7.3.China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.4.7.4.China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.8.Japan
      • 9.4.8.1.Overview
      • 9.4.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.8.3.Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.4.8.4.Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.9.South Korea
      • 9.4.9.1.Overview
      • 9.4.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.9.3.South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.4.9.4.South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.10.Australia
      • 9.4.10.1.Overview
      • 9.4.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.10.3.Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.4.10.4.Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.11.Thailand
      • 9.4.11.1.Overview
      • 9.4.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.11.3.Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.4.11.4.Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.12.Indonesia
      • 9.4.12.1.Overview
      • 9.4.12.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.12.3.Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.4.12.4.Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.13.Philippines
      • 9.4.13.1.Overview
      • 9.4.13.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.13.3.Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.4.13.4.Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.14.Rest of APAC
      • 9.4.14.1.Overview
      • 9.4.14.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.14.3.Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.4.14.4.Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.5.Latin America
    • 9.5.1.Overview
    • 9.5.2.Nontuberculous Mycobacteria Key Manufacturers in Latin America
    • 9.5.3.Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.5.4.Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.5.5.Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.5.6.Brazil
      • 9.5.6.1.Overview
      • 9.5.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.6.3.Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.5.6.4.Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.5.7.Mexico
      • 9.5.7.1.Overview
      • 9.5.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.7.3.Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.5.7.4.Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.5.8.Argentina
      • 9.5.8.1.Overview
      • 9.5.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.8.3.Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.5.8.4.Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.5.9.Colombia
      • 9.5.9.1.Overview
      • 9.5.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.9.3.Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.5.9.4.Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.5.10.Rest of LATAM
      • 9.5.10.1.Overview
      • 9.5.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.10.3.Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.5.10.4.Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.6.Middle East and Africa
    • 9.6.1.Overview
    • 9.6.2.Nontuberculous Mycobacteria Key Manufacturers in Middle East and Africa
    • 9.6.3.Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.6.4.Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.6.5.Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.6.6.Saudi Arabia
      • 9.6.6.1.Overview
      • 9.6.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.6.3.Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.6.6.4.Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.6.7.United Arab Emirates
      • 9.6.7.1.Overview
      • 9.6.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.7.3.United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.6.7.4.United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.6.8.Israel
      • 9.6.8.1.Overview
      • 9.6.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.8.3.Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.6.8.4.Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.6.9.Turkey
      • 9.6.9.1.Overview
      • 9.6.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.9.3.Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.6.9.4.Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.6.10.Algeria
      • 9.6.10.1.Overview
      • 9.6.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.10.3.Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.6.10.4.Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.6.11.Egypt
      • 9.6.11.1.Overview
      • 9.6.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.11.3.Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.6.11.4.Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.6.12.Rest of MEA
      • 9.6.12.1.Overview
      • 9.6.12.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.12.3.Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.6.12.4.Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

10.Key Vendor Analysis- Nontuberculous Mycobacteria Industry

  • 10.1.Competitive Dashboard
  • 10.2.Company Profiles
    • 10.2.1.Insmed, RedHill Biopharma Ltd
    • 10.2.2.Novartis AG
    • 10.2.3.Paratek Pharmaceuticals Inc
    • 10.2.4.Janssen
    • 10.2.5.RevImmune
    • 10.2.6.Nobelpharma Co Ltd
    • 10.2.7.Others

11.360 Degree Analyst View

12.Appendix

  • 12.1.Research Methodology
  • 12.2.References
  • 12.3.Abbreviations
  • 12.4.Disclaimer
  • 12.5.Contact Us